

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

AUG 20 1993

Re: Suprane™
Docket No. 92E-0471

#24

Charles E. Van Horn
Patent Policy and Projects Administrator
Office of the Assistant Commissioner for Patents
U.S. Patent and Trademark Office
Crystal Park Building 2, Suite 919
Washington, DC 20231

Dear Mr. Van Horn:

This is in regard to the patent term extension application for U.S. Patent No. 4,762,856 filed by Anaquest, Inc. under 35 U.S.C. § 156. The patent claims the human drug product Suprane™ (desflurane), NDA 20-118.

In the February 9, 1993, issue of the Federal Register (58 Fed. Reg. 7,790), the Food and Drug Administration published its determination of this product's regulatory review period, as required under 35 U.S.C. § 156(d)(2)(A). The notice provided that on or before August 8, 1993, 180 days after the publication of the determination, any interested person could file a petition with FDA under 35 U.S.C. § 156(d)(2)(B)(i) for a determination of whether the patent term extension applicant acted with due diligence during the regulatory review period.

The 180-day period for filing a due diligence petition pursuant to this notice has expired and FDA has received no such petition. Therefore, FDA considers the regulatory review period determination to be final.

Please let me know if we can provide further assistance.

Sincerely yours,



Ronald L. Wilson
Director

Health Assessment Policy Staff
Office of Health Affairs

cc: Hollis G. Schoepke, Ph.D.
Senior Vice President
Research and Development
Anaquest, Inc.
110 Allen Road
P.O. Box 804
Liberty Corner, N.J. 07938

RECEIVED
93 AUG 27 AM 10:32
DEPUTY ASSISTANT
COMMISSIONER FOR PATENTS